• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

    6/30/25 11:05:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email

    Company announcement – No. 16 / 2025

    Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

    Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.

    In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of June 30, 2025.



     



    Date
    Number of shares

    (nominal value of DKK 1 each)
    Share capital

    (nominal value in DKK)
    Number of voting rights
    June 30, 202571,343,80471,343,80471,343,804

    The Company's Articles of Association are available on the Company's website https://www.zealandpharma.com.

    # # #

    About Zealand Pharma A/S

    Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products.

    Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

    Contact

    Adam Lange (Investors)

    Vice President, Investor Relations

    [email protected]

    Neshat Ahmadi (Investors)

    Investor Relations Manager

    [email protected]

    Anna Krassowska (Investors and Media)

    Vice President, Investor Relations & Corporate Communications

    [email protected]



    Primary Logo

    Get the next $ZEAL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

      Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the ex

      6/30/25 11:05:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

      Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapiesUnique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenha

      6/18/25 11:29:44 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma increases its share capital as a result of the exercise of employee warrants

      Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

      6/6/25 4:00:00 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Zealand Pharma A/S

      15F-12B - Zealand Pharma A/S (0001674988) (Filer)

      9/30/22 5:24:36 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:20:13 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:16:47 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Leadership Updates

    Live Leadership Updates

    See more
    • Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

      Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

      5/19/25 9:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

      Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

      4/23/25 9:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

      Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

      11/30/23 2:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on Zealand Pharma

      Berenberg initiated coverage of Zealand Pharma with a rating of Buy

      3/5/24 7:30:01 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Zealand Pharma

      Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

      8/8/23 7:40:54 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma downgraded by Morgan Stanley

      Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

      11/16/22 9:37:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Financials

    Live finance-specific insights

    See more
    • Zealand Pharma increases its share capital as a result of the exercise of employee warrants

      Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

      6/6/25 4:00:00 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma Announces Financial Results for the First Three Months of 2025

      Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to establish the leading amylin-based franchise.Enrolled the last participant in the large, global Phase 2 ZUPREME-1 trial with petrelintide in people with overweight or obesity, thre

      5/8/25 1:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

      Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Ke

      5/1/25 11:05:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

      SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

      2/14/22 12:27:01 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

      2/3/21 1:13:21 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care